Anti-PCSK9 Drugs: An Ingenious Solution For A Problem That's Mostly Already Solved
On Friday, for the first time, we saw the full data from the FOURIER clinical trial of Amgen’s cholesterol-lowering antibody, evolocumab (Repatha™). Depending on who you listen to, it was either “the most important study in at least 20 years” or a damp squib. So what does FOURIER really tell us? And how will it change management of patients with cardiovascular disease?